AI-native biotech research
Your thesis. Compiled.
Most biotech platforms put AI on top of a database. BioSniper built the data, source links, and research workflow for AI—so your criteria can be checked across every covered biotech company, with sources.
See supported fields and evidence rules. How we verify →
A real protocol run, not a scripted demo
Below is an actual stored company decision from Spotter; the executed checks, findings, and source evidence are shown together, with no login required.
AI OverviewAI overview is shown in English only.
Rocket Pharmaceuticals Inc. is a late-stage biotechnology company developing gene therapies for rare, monogenic diseases, with a focus on cardiovascular indications and a pipeline including RP-L102 for Fanconi Anemia and RP-L301 for Pyruvate Kinase Deficiency.
- Rocket Pharmaceuticals is advancing clinical programs for rare diseases, including RP-L102 for Fanconi Anemia (FA) and RP-L301 for Pyruvate Kinase Deficiency (PKD), with regulatory interactions ongoing [sec · filed 2025-04-30].
- The company operates a ~100,000 sq. ft. in-house AAV cGMP manufacturing facility in Cranbury, New Jersey to support clinical and future commercial endeavors [sec · filed 2026-04-06].
- As of June 30, 2026, the company reported cash & equivalents of $225.8M, no revenue, net income of $123.2M (driven by a $178.2M priority review voucher sale), shareholders' equity of $277.2M, and total debt of $19.3M [sec].
- Rocket has incurred net losses since inception, with an accumulated deficit of $1.44 billion as of December 31, 2025, and net losses of $223.1M and $258.7M for fiscal years 2025 and 2024, respectively [sec_mda · as of 2026-02-26].
- The company's near-term research focus is on rare cardiovascular gene therapies targeting genetically defined cardiomyopathies, which impact over 100,000 patients in the U.S. and EU [sec_mda · as of 2026-02-26].
What works
- Rocket has a late-stage pipeline with regulatory submissions underway, including EMA acceptance of a marketing authorization application for RP-L102 for Fanconi Anemia [sec · filed 2025-04-30].
- The company operates an in-house AAV cGMP manufacturing facility, providing internal capacity for clinical and potential commercial production [sec · filed 2026-04-06].
- Management has a proven track record of over 20 successful U.S. and international drug approvals and launches in cell and gene therapies and rare diseases [sec · filed 2026-04-06].
- The company generated significant non-dilutive income through the sale of a priority review voucher for $178.2 million in the first half of 2026, bolstering its cash position [sec_mda · as of 2026-08-10].
What to weigh
- Rocket has no approved products and has not generated any revenue from product sales since inception, relying on external financing and non-dilutive sources to fund operations [sec_mda · as of 2026-02-26].
- The company has a history of significant operating losses, with an accumulated deficit of $1.44 billion as of December 31, 2025, and negative cash flows from operations [sec_mda · as of 2026-02-26].
- Enrollment for the Phase 2 pivotal trial of RP-L301 for PKD has not been initiated, as the company is prioritizing other programs, indicating potential delays or resource constraints [sec · filed 2025-04-30].
- The company's future capital requirements are uncertain and depend on the success of clinical trials, regulatory approvals, and potential collaborations, with R&D expenses expected to increase [sec_mda · as of 2026-02-26].
From the filings
Quoted directly from source documents.
Rocket has no approved products and has not generated revenue from product sales.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · February 26, 2026
The company sold a priority review voucher for $178.2 million in the first half of 2026.
“The increase in other income was primarily driven by the sale of the PRV for net $178.2 million.”
SEC MD&A · August 10, 2026
Rocket has an accumulated deficit of $1.44 billion as of December 31, 2025.
“have an accumulated deficit of $1.44 billion as of December 31, 2025.”
SEC MD&A · February 26, 2026
The company's near-term research focus is on rare cardiovascular gene therapies.
“Strategic Focus on Rare Cardiovascular Indications: Our near-term research and platform investments are focused on leveraging our AAV capabilities in rare cardiovascular diseases.”
SEC MD&A · February 26, 2026
Catalyst timeline
- 2020-07-06 · Phase 1 Start: Gene Therapy for Pyruvate Kinase Deficiency (PKD) — A Phase I clinical trial evaluating safety of RP-L301 for PKD has been completed.
- 2020-07-15 · Phase 2 Start: A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced — A Phase 2 trial for RP-L102 is active but not recruiting, assessing bone marrow colony-forming cell resistance.
- 2023-08-29 · Phase 1 Start: A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-Associate — A Phase 1 dose escalation trial for an AAV gene therapy is currently recruiting participants.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — The company has no products approved for sale and has never generated product revenue, relying on external funding [sec_mda · as of 2026-02-26].
- Significant accumulated deficit — Accumulated deficit of $1.44 billion as of December 31, 2025, with ongoing net losses and negative cash flows [sec_mda · as of 2026-02-26].
- Clinical trial delays or failures — Enrollment for the Phase 2 RP-L301 trial has not started due to resource prioritization, risking program timelines [sec · filed 2025-04-30].
- Dependence on additional financing — Future capital requirements are uncertain and the company expects R&D expenses to increase, requiring further funding [sec_mda · as of 2026-02-26].
What to watch
- Regulatory decisions on the marketing authorization application for RP-L102 for Fanconi Anemia, accepted by the EMA [sec · filed 2025-04-30].
- Initiation of enrollment in the Phase 2 pivotal trial for RP-L301 for Pyruvate Kinase Deficiency, which has not yet started [sec · filed 2025-04-30].
- Progress of the Phase 1 dose escalation trial for an intravenously administered AAV gene therapy (NCT05885412), which is currently recruiting [catalyst].
- Cash runway and potential need for additional financing, given the accumulated deficit and lack of product revenue [sec_mda · as of 2026-02-26].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Built on the records biotech decisions depend on.
922 companies across 7 authoritative source families, normalized so your protocol can reason across finance, trials, regulation, science, and market context.
Company fundamentals
SEC filings, runway, and financing
Clinical development
Programs, trials, endpoints, and readouts
Regulatory + science
FDA, PubMed, and patent records
Market + event context
Prices, news, and catalysts across 922 companies
Biotech Pulse
Live market · upcoming catalysts · curated insights — all at a glance.
XBI
$162.50+0.07%
IBB
$209.05+0.05%
New Trials Initiated
5,670
FDA Approvals
395
Partnership Deals
26,705
Phase 3 Completion
33%
Upcoming FDA Catalysts
PDUFA dates, AdCom meetings, readouts — free, no login.
Sep 4
Phase3 Start
BIIBPhase3_Start: A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants With Genetically Diagnosed Spinal Muscular AtrophySep 4
Phase3 Start
AZNPhase3_Start: Multicentre, Open-Label, Single-Arm, 52-Week, Ph3b Study to Evaluate the Efficacy and Safety Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Moderate-Severe Systemic Lupus Erythematosus (SLE)Sep 7
Phase3 Start
AMGNPhase3_Start: A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-controlled Study of Inebilizumab in Participants With Autoimmune HepatitisSep 8
Phase3 Start
INCYPhase3_Start: A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)Sep 11
Phase3 Start
BMYPhase3_Start: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of KarXT + KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum DisorderSep 11
Phase3 Start
NVSPhase3_Start: A 52-week Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy and Safety of Remibrutinib (LOU064) in Adult and Adolescent Participants With IgE-mediated Food AllergySep 11
Phase3 Start
BMYPhase3_Start: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of KarXT + KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum DisorderSep 15
Phase3 Start
GMABPhase3_Start: A Randomized, Open-label, Phase 3 Trial of Petosemtamab + FOLFIRI/mFOLFOX6 Versus Cetuximab or Bevacizumab + FOLFIRI/mFOLFOX6 as Second-line Treatment in Participants With RAS and BRAF Wild-type, Recurrent, Unresectable or Metastatic Colorectal CancerView Full Calendar
Upgrade for full details
Recent M&A
2026-08-30licensing: BioMarin Patent Rights - BioMarin entered into a binding term sheet with Ascendis for a global settlement and license agreement granting a non-exclusive, royalty-bearing license to certain patents for TransCon CNP/navepegritide/Yuviwel.
2026-08-27acquisition: BioXcel Therapeutics, Inc. and its subsidiaries - Stalking horse asset purchase agreement for substantially all assets, with upfront cash and contingent milestone payments.
2026-08-26acquisition: privately held Arizona-based precision machining and contract manufacturing company - Termination of previously disclosed acquisition of a 76% controlling interest in a precision machining company.
AI-native, from the data up
Not AI added to a database. A research system built for AI.
Tell BioSniper what matters. It checks every covered biotech company and shows the evidence—so you do not have to research them one by one.